Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Russell Investments Group Ltd.

Russell Investments Group Ltd. boosted its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) by 4,810.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 35,745 shares of the company's stock after acquiring an additional 35,017 shares during the period. Russell Investments Group Ltd.'s holdings in Nurix Therapeutics were worth $673,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in the business. Barclays PLC lifted its stake in shares of Nurix Therapeutics by 77.9% in the 3rd quarter. Barclays PLC now owns 128,344 shares of the company's stock valued at $2,884,000 after purchasing an additional 56,190 shares during the last quarter. Geode Capital Management LLC raised its holdings in Nurix Therapeutics by 9.6% in the 3rd quarter. Geode Capital Management LLC now owns 1,448,040 shares of the company's stock valued at $32,544,000 after buying an additional 126,306 shares during the period. Franklin Resources Inc. lifted its position in Nurix Therapeutics by 52.4% in the third quarter. Franklin Resources Inc. now owns 123,101 shares of the company's stock valued at $2,766,000 after buying an additional 42,315 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in Nurix Therapeutics during the third quarter worth about $7,879,000. Finally, JPMorgan Chase & Co. increased its position in shares of Nurix Therapeutics by 85.2% during the third quarter. JPMorgan Chase & Co. now owns 68,148 shares of the company's stock valued at $1,531,000 after acquiring an additional 31,352 shares during the last quarter.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Gwenn Hansen sold 3,690 shares of the company's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total transaction of $73,246.50. Following the completion of the sale, the insider now directly owns 55,937 shares of the company's stock, valued at $1,110,349.45. This represents a 6.19 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Houte Hans Van sold 2,811 shares of the stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $19.85, for a total value of $55,798.35. Following the sale, the chief financial officer now directly owns 39,549 shares of the company's stock, valued at $785,047.65. The trade was a 6.64 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 12,326 shares of company stock worth $213,449. 7.40% of the stock is owned by insiders.

Nurix Therapeutics Price Performance

Shares of Nurix Therapeutics stock traded up $0.04 during trading hours on Friday, hitting $11.56. The company had a trading volume of 589,138 shares, compared to its average volume of 894,827. The company's 50-day moving average is $12.58 and its two-hundred day moving average is $18.41. The company has a market cap of $881.29 million, a P/E ratio of -4.00 and a beta of 2.23. Nurix Therapeutics, Inc. has a twelve month low of $8.18 and a twelve month high of $29.56.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Tuesday, April 8th. The company reported ($0.67) EPS for the quarter, topping analysts' consensus estimates of ($0.72) by $0.05. The business had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the previous year, the firm earned ($0.76) earnings per share. Sell-side analysts expect that Nurix Therapeutics, Inc. will post -2.99 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently weighed in on NRIX shares. Wells Fargo & Company dropped their target price on shares of Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. JPMorgan Chase & Co. cut their price objective on Nurix Therapeutics from $31.00 to $30.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Leerink Partners assumed coverage on Nurix Therapeutics in a report on Monday, March 17th. They set a "market perform" rating and a $16.00 target price for the company. Morgan Stanley raised their price objective on shares of Nurix Therapeutics from $16.00 to $17.00 and gave the company an "equal weight" rating in a research note on Monday, February 3rd. Finally, Leerink Partnrs raised shares of Nurix Therapeutics to a "hold" rating in a research note on Monday, March 17th. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $30.44.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.